Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs Stitch Fix Inc (SFIX) Price & Performance

Ascendis Pharma A/STrade
Stitch Fix IncTrade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs Stitch Fix Inc — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Stitch Fix Inc trades at $3.79 (market cap $530.37M). The key difference: Ascendis Pharma A/S is far larger — about 31.6× Stitch Fix Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.

ASNDSFIX
Market Cap
$16.78B$530.37M
Sector
HealthConsumer Cyclical
52-Week High
$277.18$5.83
52-Week Low
$189.74$3.06
Enterprise Value
$17.15B$418.08M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.

ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.

Stitch Fix Inc

Stitch Fix (SFIX) trades at $4.20, up 4.22% today, showing stabilization after a multi-year decline. The stock is technically bullish with strong moving average signals, while fundamentals reflect a turnaround with revenue stabilizing at $1.27B and net losses narrowing to -$28.74M in 2025. Recent news highlights AI-driven personalization gains and a debt-free balance sheet, supporting a potential recovery narrative.

The outlook hinges on execution of the turnaround; improving client growth and cost controls offer upside, but persistent losses and consumer spending pressures pose risks. Analysts are cautious with a $4.75 price target and 63.6% hold rating, suggesting the stock may be fairly valued amid its recovery phase.

Returns comparison

Trailing returns across standard periods

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About Stitch Fix Inc

Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.

Read more on SFIX